We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current ATRX market cap is 31.05k. The company's latest EPS is USD -0.3786 and P/E is -2.61.
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 76k | 252k | 0 | 0 | 0 |
| Operating Income | -15.8M | -11.32M | -2.04M | -674k | -1.62M |
| Net Income | -17.82M | -13.48M | -5.31M | -8.41M | -2.73M |
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 5.14M | 420k | 1,000 | 196k | 79k |
| Total Liabilities | 2.21M | 10.31M | 14.77M | 25.3M | 22.27M |
| Total Equity | 2.93M | -9.89M | -14.77M | -25.11M | -22.19M |
| Year End 31 December 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -9.61M | -8.74M | -588k | -665k | -1.42M |
| Investing | -74k | N/A | N/A | N/A | N/A |
| Financing | 13.5M | 4.87M | 539k | 739k | 1.37M |
| Market Cap | 31.05k |
| Price to Earnings Ratio | -2.61 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 225 |
| Price to Book Ratio | -0.32 |
| Dividend Yield | - |
| Shares Outstanding | 7.22M |
| Average Volume (1 week) | 1.58k |
| Average Volume (1 Month) | 91.62k |
| 52 Week Change | -92.90% |
| 52 Week High | 0.08 |
| 52 Week Low | 0.003 |
| Spread (Intraday) | 0.01 (93.33%) |
| Company Name | Adhera Therapeutics Inc (PK) |
| Address |
651 n broad st suite 201 middletown, delaware 19709 |
| Website | https:// |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
